Supplier
Glencoe Regional Health Services
Glencoe Regional Health Services was paid $4.32M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoGLENCOE REGIONAL HEALTH SERVICES
GLENCOE, MN 55336
GLENCOE, MN 55336
33aNPI1508885633assigned 07/19/2006
33bProvider typePharmacy
28Total paid$4.32M
24GClaims123,409
24DCodes billed85
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pharmacy providers in Minnesota
Rank by total paid#1 of 29
Median peer was paid$2K
This provider vs. median1,940×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,846 | $200K | |
| 2019 | 20,165 | $719K | |
| 2020 | 15,526 | $524K | |
| 2021 | 19,166 | $725K | |
| 2022 | 18,214 | $779K | |
| 2023 | 18,979 | $747K | |
| 2024incomplete | 13,513 | $630K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 37,437 | 28,351 | $1.20M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 18,252 | 13,449 | $812K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 4,069 | 3,640 | $383K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.6% | 3,082 | 2,631 | $286K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.8% | 829 | 806 | $120K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.7% | 6,532 | 6,219 | $117K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 782 | 726 | $95K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 2,951 | 2,758 | $83K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | 1.9% | 1,493 | 1,302 | $81K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.7% | 535 | 419 | $75K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 895 | 868 | $74K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.6% | 1,528 | 1,412 | $70K |
73 more codes
| 36415 | Collection of venous blood by venipuncture | 1.5% | 7,618 | $66K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.5% | 1,369 | $63K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 428 | $61K |
| X5622 | 1.4% | 1,821 | $59K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 693 | $50K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.0% | 767 | $44K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.0% | 1,984 | $44K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.0% | 1,001 | $43K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 387 | $37K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,435 | $34K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 372 | $33K |
| 80053 | Comprehensive metabolic panel | <1% | 725 | $30K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 920 | $28K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 629 | $27K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 503 | $24K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 382 | $24K |
| 86140 | <1% | 1,110 | $21K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,562 | $21K |
| 92551 | <1% | 2,989 | $18K | |
| 99188 | <1% | 2,170 | $17K | |
| 90461 | <1% | 497 | $14K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 370 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 513 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 399 | $11K |
| 99285 | Emergency room visit (most serious) | <1% | 71 | $10K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 133 | $10K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 116 | $9K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 64 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 219 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 611 | $6K |
| J3490 | Unclassified drugs | <1% | 431 | $6K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 695 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 148 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,055 | $5K |
| 87081 | <1% | 305 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 114 | $4K |
| 90686 | <1% | 1,893 | $4K | |
| 99173 | <1% | 3,045 | $4K | |
| 91322 | <1% | 31 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41 | $4K |
| 11721 | <1% | 276 | $3K | |
| 0002A | <1% | 103 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 43 | $3K |
| 0001A | <1% | 109 | $3K | |
| 80061 | Lipid panel | <1% | 56 | $3K |
| 96127 | <1% | 855 | $3K | |
| 83690 | <1% | 57 | $2K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 330 | $1K |
| 84484 | <1% | 46 | $1K | |
| 81025 | <1% | 36 | $1K | |
| 90480 | <1% | 31 | $951.95 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 63 | $858.72 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 27 | $703.09 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 20 | $596.15 |
| 81003 | <1% | 43 | $432.57 | |
| 83735 | <1% | 12 | $418.09 | |
| 81001 | <1% | 28 | $417.96 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13 | $411.27 |
| 90656 | <1% | 96 | $376.67 | |
| 85027 | <1% | 12 | $370.88 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 86 | $362.00 |
| 0054A | <1% | 12 | $325.28 | |
| 0124A | <1% | 12 | $293.99 | |
| G0008 | Administration of influenza virus vaccine | <1% | 14 | $97.71 |
| 1111F | 0% | 810 | $0.00 | |
| 3044F | 0% | 52 | $0.00 | |
| 90651 | 0% | 12 | $0.00 | |
| 90734 | 0% | 17 | $0.00 | |
| 90670 | 0% | 37 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 22 | $0.00 |
| 90715 | 0% | 13 | $0.00 | |
| 90648 | 0% | 53 | $0.00 | |
| 90633 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLESKE, JULIE (CREDENTIALING COORDINATOR)